Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting

Business Wire May 2, 2019

Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th

Business Wire April 30, 2019

Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference

Business Wire April 1, 2019

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress

Business Wire March 14, 2019

The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

Benzinga.com  March 14, 2019

Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference

Business Wire March 13, 2019

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14

Business Wire February 28, 2019

Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Business Wire February 19, 2019

Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

Business Wire February 14, 2019

62 Biggest Movers From Yesterday

Benzinga.com  February 7, 2019

48 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  February 6, 2019

Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering

Business Wire February 6, 2019

The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Benzinga.com  February 6, 2019

Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

Business Wire February 5, 2019

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 30, 2019

58 Biggest Movers From Yesterday

Benzinga.com  January 17, 2019

Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors

Business Wire January 4, 2019

Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment

Business Wire January 3, 2019

Catabasis Pharmaceuticals Announces Reverse Stock Split

Business Wire December 24, 2018

Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 28, 2018